



THE PLATFORM GROUP

Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

Correction to the publication dated 02.10.2025, 10:25 a.m. (CEST) - The Platform Group AG raises its forecast for 2026 to EUR 1 billion in sales and EUR 70-80 million in EBITDA - three acquisitions in the pharmaceutical sector and expansion in the Optics & Hearing segment

Correction to the second paragraph: The information regarding a shareholding and its legal company name was not presented correctly. The corrected announcement is reproduced in full below.

Düsseldorf, 6 October 2025. The Management Board of The Platform Group AG (ISIN: DE000A2QEFA1) has decided to raise its medium-term forecast for the 2026 financial year. Net sales of around EUR 1.0 billion (previous forecast: over EUR 860 million) and adjusted EBITDA in a range of EUR 70 million to EUR 80 million (previous forecast: over EUR 64 million) are now expected. Gross merchandise volume (GMV) is expected to rise to around EUR 1.7 billion (previous forecast: EUR 1.6 billion). The forecast for the 2025 financial year remains unchanged.

In addition to TPG's positive earnings performance and organic growth, the increase is attributable to the majority acquisition of Cologne-based Apothekia GmbH, which operates a pharmaceutical training platform. In addition, TPG holds a 50% stake in the Vienna-based Contracta Group, which owns 100% of the Austrian company Pharmosan and 79.5% of the Czech company Vamida. Furthermore, further acquisitions in the Optics & Hearing sector are taking place in October. The "Service & Retail Goods" segment will be expanded as a result and will be renamed "Pharma & Service Goods" in the future. The transactions are expected to close by the end of 2025, subject to approval by the relevant antitrust authorities.

In addition, The Platform Group has entered into agreements to acquire two further companies in the "Optics & Hearing" segment. Together, these companies generate sales in the single-digit million range with an EBITDA margin of around 24%.

Contact:

Investor Relations

Nathalie Richert

Head of Investor Relations

ir@the-platform-group.com

Schloss Elbroich | Am Falder 4 | 40589 Düsseldorf | Germany

corporate.the-platform-group.com